Document:

Exhibit 10.7

 

Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

COMMERCIAL
SPONSORED RESEARCH AGREEMENT

 

THIS AGREEMENT is entered
into this 21sr day of June, 2016 (the “Effective Date”) by Sanford Burnham Prebys Medical Discovery Institute,
a California not-for-profit public benefit corporation with an address at 10901 N. Torrey Pines Road, La Jolla, California 92037
(“Institute”) and Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address
at 4150 Sainte-Catherine St West, Suite 550, Montreal, Quebec, H3Z 2Y5, Canada (hereinafter refe1Ted to as “Sponsor”).

 

WHEREAS, the research
program contemplated by this Agreement is of mutual interest and benefit to the Institute and Sponsor and may further the research
mission of the Institute in a manner consistent with its status as a non-profit, tax-exempt, research institution; and

 

WHEREAS, the research
program contemplated by this Agreement is to be funded by Sponsor, and carried out by Yu Yamaguchi, M.D., Ph.D., an employee
of Institute, as the Principal Investigator; and

 

WHEREAS, Sponsor desires
to provide funding to support said research program according to the terms and conditions of this Agreement; and

 

WHEREAS, the Institute
desires to accept such funding according to the terms and conditions of this Agreement.

 

NOW, THEREFORE, the
parties agree as follows:

 

1. Scope of Work/ Performance
Period

 

(a) Subject to the terms
and conditions of this Agreement, the Institute agrees to use reasonable efforts to cause the Principal Investigator to conduct
the research program entitled “Efficacy Testing of Palovarotene on a Mouse Model of MHE” (“Research Program”)
in accordance with Appendix A attached hereto and incorporated herein by reference. The parties acknowledge that
the Research Program will be conducted during the period commencing on the Effective Date above and end within twelve (12)
to eighteen (18) months therefrom (“Performance Period”), and may be extended thereafter by mutual written agreement
of the parties.

 

(b) The Research Program
shall be conducted at the Institute by the Principal Investigator and by such additional research staff working under the Principal
Investigator’s supervision as the Principal Investigator shall reasonably determine in consultation with the Institute. The
Research Program will be performed in strict accordance with applicable regulations and policies, including without limitation,
laws governing the care and use of laboratory animals for research, including the Institute of Laboratory Animal Resources Guide
for the Care and Use of Laboratory Animals, the Laboratory Animal Welfare Regulations (Code of Federal Regulations Title 9);
the Public Health Service Policy on Humane Care and Use of Laboratory Animals and/or any similar law; the requirements of the responsible
institutional animal care and use committee or similar, authorized committee, and other applicable federal state, and local laws,
regulations, and policies.

    	Page 1

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

(c) The Research Program
may include a training component where postdoctoral trainees would perform some aspects of the Research Program. A training component
would provide postdoctoral trainees in-depth opportunities to learn about the Research Program’s underlying science and
technology, and the design and interpretation of research results. The Principal Investigator would provide mentoring, but remain
ultimately responsible for, all aspects of the postdoctoral trainees’ work under the Research Program, which could involve,
among other things, providing training in research design and methods, data interpretation, verbal and written communication and
career advice.

 

(d) Any material alteration
in or significant amendment to the Research Program must be approved in writing by both the Institute and Sponsor prior to such
alteration or amendment becoming effective.

 

2. Principal Investigator

 

In the event that Principal
Investigator becomes unable to complete the Research Program for any reason, the Institute will, to the extent possible, propose
a substitute principal investigator with qualifications reasonably similar to Dr. Yamaguchi for Sponsor’s approval. In the
event Sponsor and the Institute agree upon a substitute Principal Investigator, this Agreement shall continue in full force and
effect.

 

3.

 

(a) Sponsor agrees,
subject to the terms and conditions of this Agreement, to provide to the Institute funds in an amount equal to the costs of conducting
the Research Program, which costs shall be allocated in accordance with the Research Program budget but which costs shall not exceed
[******] during the term of the Agreement. Sponsor
shall make such payments to the Institute in accordance with the following schedule:

 

(i) upon execution of
this Agreement: [******];

 

(ii) upon completion
of Aim 1 of the Research Program to Sponsor’s reasonable satisfaction: [******];

 

(iii) upon completion
of Aim 2 of the Research Program to Sponsor’s reasonable satisfaction: [******]; and

 

(iv) upon submission
of the Final Report in a form reasonably acceptable to Sponsor: [******];

 

(b) It is anticipated
that the parties may desire to extend the Research Program beyond the Performance Period. If both pai1ies desire to extend the
Research Program, they shall make good faith efforts to conclude negotiations of scope and budget three (3) months prior to the
scheduled termination of this Agreement.

    	Page 2

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

(c) Any additional payments
must be approved in advance by Sponsor in writing.

 

(d) Any equipment purchased
by Institute as part of the Research Program with Institute’s own funds for use at the Institute shall be owned by the Institute,
shall be physically located at the Institute and shall remain the property of the Institute following completion of the Research
Program. Any equipment or materials purchased by Sponsor for use by Institute as part of the Research Program will be owned by
Sponsor and will be used by Institute solely for purposes of the Research Program and will be returned to Sponsor at the end of
the Research Program.

 

(e) Payment of all sums
due hereunder shall be made by check payable as follows:

 

Sanford Burnham Prebys Medical
Discovery Institute

Attn: Vice President, Finance
& Controller

Finance Department

10901 N. Torrey Pines Road

La Jolla, CA 92037

 

Re: (YAMAGUCHI, Clementia Pharmaceuticals,
CSRA 16-10)

 

(f) Nothing contained
herein shall be construed as requiring the Institute or the Principal Investigator or any Institute research staff to work on any
project or process which is prohibited by law or by any international treaty to which the United States of America is a party,
or which may be harmful or detrimental to public health, safety or good laboratory practices or which may be considered to be immoral.

 

(g) Third Party Licenses.
Sponsor will be responsible for negotiating and entering into any third party license(s) that Sponsor determines may be necessary
for carrying out the Research Program under this Agreement. Sponsor will be solely responsible for obtaining any licenses and/or
other agreements necessary to pursue the Research Program under this Agreement and any costs for such licenses are not already
included in the funding and payment set forth in this Section 3.

 

4. Publications

 

Sponsor acknowledges
that the Institute is a nonprofit research center and that the Principal Investigator shall be free to publish the results of his
research without restraint. The Institute agrees to direct the Principal Investigator, and by acknowledging this Agreement the
Principal Investigator accepts his obligation, to (i) report in writing to Sponsor any manuscript or draft presentation regarding
the Research Program at least thirty (30) days prior to publication; and (ii) notify Sponsor of any conference at which the results
of the Research Program will be presented. Sponsor agrees to hold all such submissions and information in confidence. Sponsor agrees
to promptly notify the Institute and the Principal Investigator if any action is necessary to delete Sponsor Confidential Information
(as hereinafter defined). If Sponsor believes it prudent to secure patent protection for a patentable invention(s) disclosed in
any such material, then, upon Sponsor’s written request, Institute agrees to delay the publication for up to an additional
sixty (60) days to permit Sponsor to pursue such patent protection. If requested by Sponsor, the

    	Page 3

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

Institute agrees to include
in any publication of the results of the Research Program acknowledgment of Sponsor’s financial support of the Research
Program. Sponsor also agrees that Principal Investigator may disclose such financial support if required by a publisher as a condition
of publication. If, after the initial thirty (30) days from the date that P1incipa1 Investigator provides Sponsor with the proposed
publication Sponsor does not respond, then Principal Investigator shall be free to proceed with the publication or presentation
of the results without further delay.

 

5. Sponsor Confidential
Information

 

(a) The parties acknowledge
that Sponsor may disclose to the Institute certain confidential and proprietary info1mation of Sponsor. Such information may take
the form of, among other things: data concerning scientific discoveries made by Sponsor; Sponsor’s marketing plans; Sponsor’s
strategy for or status of regulatory approval; or Sponsor’s forecasts of sales and sales data (hereafter referred to collectively
as “Sponsor Confidential Information”).

 

(b) Sponsor acknowledges
and agrees that none of the information described in subparagraph (a) above will be considered Sponsor Confidential Information
for purposes of this Agreement, unless said information is disclosed to the Institute by Sponsor in writing and is clearly marked
as confidential at the time of disclosure; is verbally disclosed to the Institute by Sponsor, and followed within thirty (30) days
of such verbal disclosure by a writing from Sponsor confirming such disclosure and indicating that such disclosure is confidential;
or is information of a character that Institute would reasonable know is confidential, due to the nature of the information and
the circumstances of its disclosure.

 

(c) Sponsor further
acknowledges and agrees that solely for purposes of Institute’s publication rights under Section 4., Sponsor Confidential
Info1mation shall not include data generated solely by the Institute, or the Principal Investigator or his associates, co-workers
or staff in connection with the Research Program. For the sake of clarification, the inclusion of Institute Confidential Information
or other pre-existing data of Institute’s in results or for generation of the Results does not change the nature of such
information to be that of Sponsor’s. In such an event, the parties will cooperate in good faith, including the execution
of additional agreements or other documents, to ensure that Sponsor has the right to use results notwithstanding the inclusion
of Institute confidential information. If Sponsor desires to use the data and results that are Institute Confidential Information
in any publication of Sponsor’s own, Sponsor agrees to first coordinate with Dr. Yamaguchi in order to preserve Dr. Yamaguchi’s ability to publish the data in peer-reviewed publications.

 

(d) Subject to the terms
and conditions of this Agreement, the Institute hereby agrees that during the term of this Agreement and for a period of five
(5) years thereafter, the Principal Investigator and Institute shall (i) use its best efforts to cause employees, associates, co-workers
and staff not to publicly divulge, disseminate, publish or otherwise disclose any Sponsor Confidential Information without Sponsor’s
prior written consent and to ensure that such employees, associates, co-workers and staff are bound by obligations of confidentiality
at least as stringent as this Agreement; (ii) limit access to Sponsor Confidential Information to those associates, co-workers
and staff who have a need to know such Sponsor Confidential Information in connection with the Research Program, and (iii) return
to Sponsor any

    	Page 4

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

documents, drawings,
sketches, designs, products or samples containing Sponsor Confidential Information, together with any copies thereof, promptly
upon Sponsor’s request therefor.

 

(e) Sponsor and the
Institute acknowledge and agree that the obligations set out in this Paragraph 5 shall not apply to any portion of the Sponsor
Confidential Information which the Institute can demonstrate by competent evidence:

 

(i) was at the time
of disclosure to the Institute, or thereafter became (prior to its publication, divulgence or use) through no fault of the Institute,
a part of the public domain by publication or otherwise; or

 

(ii) the Institute can
demonstrate by written evidence was already properly and lawfully in its possession at the time it was received from Sponsor; or

 

(iii) was lawfully received
by the Institute from a third party who was under no obligation of confidentiality with respect thereto; or

 

(iv) is required by
law or judicial process (including patent applications) to be disclosed provided that Institute gives notice to Sponsor of such
requirement reasonably in advance of disclosure and cooperates with Sponsor’s lawful efforts to reduce or avoid disclosure;
or

 

(v) is independently
developed by the Institute without reference to Sponsor Confidential Information as demonstrated by contemporaneous written records.

 

(f) Sponsor agrees that
it shall not disclose to the Institute any information which is Sponsor Confidential Information except to the extent Sponsor reasonably
believes to be necessary to fulfill its obligations under this Agreement.

 

(g) Sponsor agrees to
treat information disclosed to it by the Institute in the same manner as the Institute agrees to treat Sponsor’s Confidential
Information hereunder.

 

6. Intellectual Property

 

(a) Inventorship shall
be determined according to United States patent law. Inventions made during the performance of the Research Program that constitute
a reduction to practice of Sponsor’s prior conception or that rely on, or incorporate Sponsor’s Confidential Information
as defined in Section 5 will be referred to as “Sponsor IP.” Inventions other than Sponsor IP made solely by inventors
or authors who are Institute employees, will be referred to as “Institute IP.” Inventions other than Sponsor IP made
during the performance of the Research Program jointly by inventors who are Institute employees and Sponsor’s employees will
be referred to as “Joint IP.”

 

(b) Institute will promptly
provide Sponsor with a copy of any invention disclosure submitted to it by the Principal Investigator or any Institute employee.

 

(c) Sponsor hereby grants
to Institute an irrevocable, royalty-free, worldwide exclusive license to use Sponsor IP, including Sponsor’s share of any
Joint IP, for its own

    	Page 5

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

non-commercial, internal
research and educational purposes only. Institute will provide all documents and other support reasonably requested by Sponsor,
at Sponsor’s sole expense, to enable Sponsor to effectuate its rights in Sponsor IP or Joint IP as set forth herein. Sponsor
may request that Institute file a patent application covering Institute IP or Joint IP, provided Sponsor agrees to reimburse Institute
for all patent costs. Sponsor has the right to review all filings and office actions related to these patent applications for so
long as Sponsor is reimbursing Institute for all such patent costs.

 

(d) Institute acknowledges
and agrees that Sponsor IP, as defined in 6.(a), will be Controlled by Sponsor. The term “Control” as used herein,
means that Sponsor will be solely responsible for all decisions regarding patent or other protection, licensing and commercialization
and Institute will not, without Sponsor’s prior written consent, assign, license, transfer or otherwise encumber Sponsor
IP, subject to Institute’s right to use Sponsor IP as set forth in 6.(c).

 

(e) Institute hereby
grants to Sponsor an exclusive option to an exclusive license to any Sponsor IP, Institute IP or Institute’s right in Joint
IP. Sponsor must exercise the option in writing to Institute within three (3) months after the Institute discloses the invention
to Sponsor. The license for Institute IP and Institute’s rights in Joint IP shall require Sponsor to (1) use commercially
reasonable efforts to commercialize products utilizing the licensed technology; and (2) pay a reasonable royalty to Institute.
The license will contain other commercially standard terms and conditions. If, after good faith negotiations, a license has not
been negotiated, or if the Sponsor decides to forgo the option, Institute shall be free to offer commercial license rights to any
third party or to dispose of institute IP or Institute’s rights in Joint IP as it deems appropriate.

 

7. Indemnification

 

(a) Sponsor shall indemnify, defend and hold harmless the Institute, its board members, officers, agents and employees, including the Principal Investigator
(the “Institute Indemnitees”) from and against any and all liability, loss, damage, claims, costs, actions, and suits,
including costs, expenses, and attorneys’ fees, arising out of, resulting from, or directly or indirectly relating to, any
claims, suits, actions, demands or judgments arising out of Sponsor’s performance under this Agreement, to the extent such
liability, loss, damage or expense is not attributable to the negligent act or omission or reckless conduct or willful misconduct
of Sponsor Indemnitees.

 

(b) The Institute shall
indemnify, defend and hold ham1less Sponsor, its board members, officers, agents and employees (the “Sponsor Indemnitees”)
from and against any and all liability, loss, damage, claims, costs, actions and suits, including costs, expenses, and attorneys’
fees, arising out of, resulting from, or directly or indirectly relating to, any claims, suits, actions, demands or judgments arising
out of the Institute’s performance, respectively, under this Agreement, to the extent such liability, loss, damage or expense
is not attributable to the negligent act or omission or reckless conduct or willful misconduct of the Sponsor Indemnitees.

    	Page 6

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

8. Termination

 

This Agreement may be
terminated upon the occurrence of any of the following events:

 

(a) The Institute terminates
this Agreement immediately upon the bankruptcy, insolvency, liquidation, dissolution or cessation of operations of Sponsor; or
the filing of any voluntary petition for bankruptcy, dissolution, liquidation or winding-up of the affairs of Sponsor; or any assignment
by Sponsor for the benefit of creditors; or the filing of any involuntary petition for bankruptcy, dissolution, liquidation or
winding-up of the affairs of Sponsor which is not dismissed within ninety (90) days of the date on which it is filed or commenced.

 

(b) The Institute may
terminate this Agreement upon fifteen (15) business days prior written notice in the event Sponsor fails to make any payment required
of Sponsor hereunder in a timely manner; provided such breach is not cured within said fifteen (15) business day notice period.

 

(c) Except as otherwise
provided above in subparagraph (b), the Institute may terminate this Agreement upon sixty (60) days prior written notice in the
event of any material breach by Sponsor of any material term or condition hereof; provided such breach is not cured within said
sixty (60) day notice period.

 

(d) Sponsor may terminate
this Agreement upon sixty (60) days prior written notice with or without cause (“cause”, as used herein, means the
material breach by the Institute of any material term of this Agreement); provided such breach is not cured within said sixty (60)
day period and Sponsor pays the Institute all costs incurred or non-cancellable commitments made by Institute prior to the effective
date of termination. For purposes of clarity, non-cancellable commitments is limited to equipment, supplies, materials or vendor
services necessary for conducting the Research Program, and excludes personnel costs, such commitments to post-doctoral fellows
and other learners participating in the training component of the Research Program.

 

9. Effect of Termination

 

(a) Except as otherwise
provided herein, termination of this Agreement shall not be construed to release either party from any obligation hereunder which
has matured prior to the date of said termination. In the event Sponsor terminates this Agreement without cause or in the event
the Institute terminates this Agreement in accordance with any of subparagraphs (a), (b), or (c) of Paragraph 8 above, the Institute
shall be under no further obligation to grant to Sponsor any further options or licenses hereunder that have not arisen or been
exercised as of the date of termination. In the event of termination pursuant to subparagraph 8(a), any outstanding licenses or
options granted to Sponsor prior to the date of such termination shall concurrently terminate.

 

(b) Upon early termination
by Sponsor or the Institute, under Paragraph 8, the Institute will proceed in orderly fashion to terminate any outstanding commitments
and to phase down the Research Program. All reasonable costs to the Institute associated with early termination will be considered
reimbursable costs, including costs incurred prior to the notice of termination but which have not yet been reimbursed, and commitments
existing at the time the

    	Page 7

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

notice of termination
is received. Any funds pre-paid, unexpended and uncommitted funds as described in 8(d), above, will returned to Sponsor within
forty-five (45) days following termination for any reason.

 

10. Communications and
Final Report.

 

(a) The Principal Investigator
agrees that Sponsor shall be advised of the progress of the Research Program by verbal reports as reasonably requested by Sponsor
and by written reports reviewing such progress prepared under the supervision of the Principal Investigator and submitted to Sponsor
following the written request of Sponsor, but no more frequently than semi-annually during the Performance Period.

 

(b) Upon expiration
of this Agreement, the Principal Investigator shall submit to Sponsor a final rep01t describing the progress made and the results
obtained in the Research Program (“Final Report”). The Final Report will be submitted to Sponsor within sixty (60)
days after the effective date of such expiration.

 

(c) All work under the
Agreement shall be deemed completed upon submission of the Final Report by Institute to Sponsor under this Paragraph 10.

 

(d) All communications,
reports and notices shall be delivered by hand, by confirmed email transmission or sent by first class mail postage prepaid and
addressed as follows (or at such other address as the party may have previously specified by like notice):

 

If to Sponsor:

 

Clementia Pharmaceuticals, Inc.

Attn: Michael Harvey, Ph.D.

4150 Sainte-Catherine St West,
Suite 550

Montreal, Quebec, H3Z 2Y5, Canada

 

Facsimile: 888-966-0135

Email: mharvey@clementiapharma.com

 

If to Institute:

 

Sanford Burnham Prebys Medical
Discove1y Institute

Office of Technology Management
and Commercialization

10901 North Torrey Pines Road

La Jolla, CA 92037

 

Email: legal@sbpdiscovery.org

 

(e) Subject to Paragraph
4 (Publications), all reports submitted to Sponsor under this Paragraph 10, whether verbal or in writing, shall be held in confidence
by the parties, in accordance with subparagraph 5(h) of this Agreement, except for that information which falls under the definition
of subparagraph 5(c) of this Agreement.

    	Page 8

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

11. Use of Names

 

Except as otherwise
required by law, each party agrees not to use or cite in any manner the name of the other, its employees, anything related to the
Research Program or the Principal Investigator in any commercial or non-commercial advertising, article, press release or in any
other forms of writing or publication medium without the prior written permission of the party or individual whose name or other
information is to be used.

 

12. Assignment

 

(a) Except as otherwise
provided herein, neither party may assign their rights hereunder to any third party without the prior written consent of the other
party. Any assignment in violation of this clause shall be null and void.

 

(b) In the event Sponsor
merges with another entity, is acquired by another entity, or sells all or substantially all of its assets relating to the subject
matter of this Agreement to another entity, Sponsor may assign its rights and obligations hereunder to, in the event of a merger
or acquisition, the surviving entity, and in the event of a sale, the acquiring entity, without the Institute’s consent so
long as: (i) Sponsor is not then in breach of this Agreement; (ii) the proposed assignee has available resources and sufficient
scientific, business and other expertise to satisfy Sponsor’s obligations hereunder; and (iii) Sponsor provides written notice
of the assignment to the Institute, at least thirty (30) days prior to the effective date of the proposed assignment.

 

13. General Provisions

 

(a) All rights and remedies
hereunder will be cumulative and not alternative, and this Agreement shall be construed and governed by the Jaws of the State of
California.

 

(b) This Agreement may
be amended only by written agreement signed by both parties.

 

(c) Sponsor and the
Institute agree to conduct the Research Program in accordance with all applicable Federal, State and local laws and regulations, as well as applicable regulations of the Institute.

 

(d) It is expressly
agreed by the parties hereto that the Institute and Sponsor are independent contractors and nothing in this Agreement is intended
to create an employer relationship, joint venture, or partnership between the parties. Neither party has the authority to bind
the other.

 

(e) This Agreement and
its appendices and/or attachments constitute the entire agreement between the parties with respect to the subject matter hereof
and supersedes all proposal, negotiations and other communications between the parties, whether written or oral, with respect to
the subject matter hereof.

    	Page 9

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

(f) If any provisions
of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions of this Agreement shall not be impaired thereby.

 

(g) MATERIALS, RESEARCH,
DATA AND RESULTS PROVIDED BY INSTITUTE UNDER THIS AGREEMENT ARE PROVIDED “AS IS”. THE INSTITUTE MAKES NO WARRANTY,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, TRADE SECRET, TANGIBLE RESEARCH PROPERTY, INFORMATION OR
DATA’ LICENSED OR OTHERWISE PROVIDED TO SPONSOR HEREUNDER AND HEREBY DISCLAIMS THE SAME. THE INSTITUTE SHALL NOT BE LIABLE
FOR ANY INDIRECT, CONSEQUENTIAL OR OTHER DAMAGES SUFFERED BY ANY LICENSEE OR OTHERS RESULTING FROM USE OF THE RESEARCH OR ANY SUCH
INVENTION OR PRODUCT, EXCEPT TO THE EXTENT RESULTING FROM INSTITUTE’S NEGLIGENCE OR WILLFUL MISCONDUCT. TN NO EVENT SHALL
INSTITUTE’S TOTAL LIABILITY UNDER THIS AGREEMENT EXCEED THE AMOUNT PAID BY SPONSOR FOR THE RESEARCH PROGRAM.

 

(h) This Agreement may
be executed in any number of counterparts, each of which shall be deemed an original as against the party whose signature appears
thereon, but all of which taken together shall constitute but one and the same instrument.

 

[SIGNATURE PAGE FOLLOWS]

    	Page 10

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first written above.

 

	
        SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

	
        CLEMENTIA PHARMACEUTICALS, INC.

	 	 

	By:	/s/ Kristiina Vuori	 	By:	/s/ Clarissa Desjardins
	Name: 	Kristiina Vuori, M.D., Ph.D.	 	Name: 	Clarissa Desjardins, Ph.D.
	Title: 	President	 	Title: 	President & CEO
	Date: 	6/22/2016	 	Date: 	June 23, 2016

 

PRINCIPAL INVESTIGATOR’s ACKNOWLEDGMENT:

 

I have read, understand, and agree to abide by the provisions
of this Agreement.

 

	By:	/s/ Yu Yamaguchi	 
	Name: 	Yu Yamaguchi, M.D., Ph.D.	 
	 	 	 
	Date: 	6/22/2016	 

 

APPENDIX
A

RESEARCH PROGRAM

 

Background

Sponsor is interested in pursuing ng a
preclinical study on multiple hereditary exostoses (MHE), a rare genetic bone disease characterized by the fom1ation of multiple
benign bone rumors (osteochondroma) and bone deformity. Sponsor is developing palovarotene as a potential therapy for Fibrodysplasia
Ossificans Progrcssiva (FOP) and has been interested in testing the potential therapeutic effect of palovarotene in another rare
bone disease, MHE. Dr. Yamaguchi has expertise and an appropriate mouse model for MHE testing.

 

Objective

Principal Investigator will use his expertise
and MHE mouse model to test Sponsor’s drug, palovarotene, to generate preliminary data on the potential therapeutic effect
of palovarotene in MHE.

 

Aims

	1)	Breeding of test animals: The first phase of the project is breeding to produce sufficient numbers of test animals (Fsp
1-Cre:Extlflox/flox). Two groups of mutant mice will be administered with two different doses of Palovarotene, one group of mutant
mice will be administered with vehicle only, and one group of phenotypically normal littermates will 

    	Page 11

    	

    
Sanford Burnham Prebys Medical Discovery
Institute – CONFIDENTIAL

 

be untreated. The number
of mice per group will be 10, which is sufficient to have enough statistical power. To produce these numbers of test animals,
multiple rounds of breeding are
necessary, which encompasses more than 2,000 cage-days and 50 weeks. Genotyping of animals will be performed by PCR.

 

	2)	Administration of Palvarotene for experimentation. Once a sufficient number of test animals have been produced in Aim 1, above, drug administration experiments will be performed on these mice. Palovarotene will be administered by oral gavage daily
for 6 weeks, starting P 15.

 

	3)	Evaluation of osteochnodroma formation. At the end of drug treatment in Aim 2, above, all of the mice will be sacrificed
to prepare alcian blue/alizarin red-stained whole-mount skeletal preparations. In these skeletal preparations, the formation of
osteochondromas will be assessed in long bones in limbs, rib bones, and vertebrae.

 

Training Component

The studies described above will include
a training component wherein postdoctoral trainees will perform some of the experiments. This will provide postdoctoral trainees
in-depth opportunities to learn about the underlying science and technology, and the design and interpretation of research results.
The Principal Investigator will provide mentoring for all aspects of the postdoctoral trainees’ work under the Research Program, which could involve, among other things, providing training in research design and methods, data interpretation, verbal and written
communication and career advice.

 

Estimated Project Duration: within
12 to 18 months

Total Estimated Budget: [*****] USD

    	Page 12Exhibit 4.1

 

 

 

 

 

VOTING
AND SUPPORT AGREEMENT

 

VOTING
AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 29, 2017, is by and among Rising Tide Parent Inc.,
a Delaware corporation (“Parent”), Rising Tide Merger Sub Inc., a Delaware corporation and a wholly-owned
subsidiary of Parent (“Sub”), and the Persons set forth on Schedule I attached hereto (“Stockholder”).

 

WHEREAS,
Stockholder is, as of the date hereof, the record and beneficial owner (for purposes of this Agreement, “beneficial owner”
(including “beneficially own” and other correlative terms) shall have the meaning set forth in Rule 13d-3 promulgated
under the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange
Act”)) of the number of Shares (as defined in the Merger Agreement) and Company Options (as defined in the Merger Agreement)
of West Marine, Inc., an Delaware corporation (the “Company”), as set forth opposite the name of Stockholder
on Schedule I hereto;

 

WHEREAS,
concurrently with the execution and delivery of this Agreement, Parent, Sub, and the Company are entering into an Agreement and
Plan of Merger, dated as of the date hereof (as may be amended, restated, supplemented or otherwise modified from time to time,
the “Merger Agreement”), which provides, among other things, for the merger of Sub with and into the Company
(the “Merger”), with the Company being the surviving entity of such Merger and a wholly-owned subsidiary of
Parent, upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized terms used herein without
definition shall have the respective meanings specified in the Merger Agreement); and

 

WHEREAS,
as a condition to the willingness of Parent and Sub to enter into the Merger Agreement and as an inducement and in consideration
therefor, Parent and Sub have required that Stockholder, and Stockholder has agreed to, enter into this Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth herein, and intending to be legally
bound hereby, the parties hereto agree as follows:

 

SECTION
1.      Representations and Warranties of Stockholder. Stockholder
hereby represents and warrants to Parent and Sub as follows:

 

		(a)	As
                                         of the time of execution of this Agreement, Stockholder (i) is the record or beneficial
                                         owner of the Shares and/or the Company Options (together with any Shares, Company Options
                                         or other equity securities of the Company which such Stockholder may acquire at any time
                                         during the term of this Agreement, including pursuant to any exercise of Company Options,
                                         the “Stockholder Securities”) set forth opposite Stockholder’s
                                         name on Schedule I to this Agreement and (ii) except as set forth in Schedule
                                         I to this Agreement, neither holds nor has any beneficial ownership interest in any
                                         other Shares or Company Options, RSUs or other equity securities of the Company.

 

		(b)	Stockholder
                                         has the legal capacity to execute and deliver this Agreement and to consummate the transactions
                                         contemplated hereby.

 

     

     

    

 

 

		(c)	This
                                         Agreement has been duly executed and delivered by Stockholder and, assuming this Agreement
                                         constitutes a legal, valid and binding obligation of Parent and Sub, this Agreement constitutes
                                         a legal, valid and binding obligation of Stockholder, enforceable against Stockholder
                                         in accordance with its terms, subject to the Bankruptcy and Equity Exception.

 

		(d)	Neither
                                         the execution and delivery of this Agreement nor the consummation by Stockholder of the
                                         transactions contemplated hereby will result in a violation of, or a default under, or
                                         conflict with, any Contract of any kind to which Stockholder is a party or by which Stockholder
                                         or Stockholder’s assets are bound, except for such violations, defaults or conflicts
                                         as would not prevent or materially delay Stockholder’s performance of its obligations
                                         under this Agreement. Assuming compliance with the applicable provisions of the HSR Act,
                                         and assuming all notifications, filings, registrations, permits, authorizations, consents
                                         or approvals to be obtained or made by the Company, Parent or Sub in connection with
                                         the Merger Agreement and the transactions are obtained or made, the consummation by Stockholder
                                         of the transactions contemplated hereby will not (i) violate any provision of any decree,
                                         order or judgment applicable to Stockholder, (ii) require any consent, approval, or notice
                                         under any legal requirements applicable to Stockholder, other than as required under
                                         the Exchange Act, or (iii) if such Stockholder is an entity, violate any provision of
                                         such Stockholder’s organizational documents, except in each case as would not prevent
                                         or materially delay Stockholder’s performance of its obligations under this Agreement.

 

		(e)	The
                                         Stockholder Securities and the Certificates representing the Stockholder Securities owned
                                         by Stockholder are now, and, subject to Section 3(b), at all times during the term of
                                         this Agreement will be, held by Stockholder or by a nominee or custodian for the benefit
                                         of Stockholder, free and clear of all Liens, except for (i) any such Liens arising hereunder
                                         or under the Merger Agreement and (ii) any applicable restrictions on transfer under
                                         the Securities Act, the securities Laws of any state within the United States or pursuant
                                         to any written policies of the Company with respect to restrictions upon the trading
                                         of securities under applicable securities laws (collectively, “Permitted Liens”).

 

		(f)	Stockholder
                                         has full voting power, with respect to the Shares that are Stockholder Securities, and
                                         full power of disposition, full power to issue instructions with respect to the matters
                                         set forth herein, and full power to agree to all of the matters set forth in this Agreement,
                                         in each case with respect to all of the Stockholder Securities. The Stockholder Securities
                                         are not subject to any proxy, voting trust or other agreement, arrangement or restriction
                                         with respect to the voting of such Stockholder Securities, except as provided under this
                                         Agreement.

 

		(g)	As
                                         of the time of execution of this Agreement, there is no Proceeding of any nature pending
                                         or, to the knowledge of Stockholder, threatened against Stockholder at law or equity
                                         before or by any Governmental Entity that could reasonably be expected to prevent or
                                         materially delay Stockholder’s performance of its obligations under this Agreement.

 

    -1- 

     

    

  

		(h)	Stockholder
                                         has received and reviewed a copy of the Merger Agreement. Stockholder understands and
                                         acknowledges that Parent and Sub are entering into the Merger Agreement in reliance upon
                                         Stockholder’s execution, delivery and performance of this Agreement.

 

SECTION
2.      Representations and Warranties of Parent and Sub.
Each of Parent and Sub hereby, jointly and severally, represents and warrants to Stockholder as follows:

 

		(a)	Each
                                         of Parent and Sub is an entity duly organized, validly existing and in good standing
                                         under the Laws of its jurisdiction of organization and each of Parent and Sub has the
                                         corporate power and authority to execute and deliver and perform its obligations under
                                         this Agreement and the Merger Agreement and to consummate the transactions contemplated
                                         hereby and thereby, and each has taken all necessary action to duly authorize the execution,
                                         delivery and performance of this Agreement and the Merger Agreement.

 

		(b)	This
                                         Agreement and the Merger Agreement have been duly authorized, executed and delivered
                                         by each of Parent and Sub, and, assuming this Agreement and the Merger Agreement constitute
                                         legal, valid and binding obligations of the other parties hereto and thereto, constitute
                                         the legal, valid and binding obligations of each of Parent and Sub, are enforceable against
                                         each of them in accordance with their terms, subject to the Bankruptcy and Enforceability
                                         Exception.

 

SECTION
3.      Transfer of the Shares; Other Actions.

 

		(a)	Prior
                                         to the End Date, except as otherwise expressly provided herein (including pursuant to
                                         this Section 3 or Section 4) or in the Merger Agreement, Stockholder shall
                                         not, and shall cause each of its Subsidiaries and affiliates not to: (i) directly or
                                         indirectly transfer, assign, sell, gift-over, hedge, pledge or otherwise dispose (whether
                                         by sale, liquidation, dissolution, dividend or distribution) of, enter into any derivative
                                         arrangement with respect to, or create any Lien (other than Permitted Liens) on or enter
                                         into any agreement with respect to (any of the foregoing, a “Transfer”),
                                         any or all of its Stockholder Securities; (ii) enter into any contract, option or other
                                         agreement, arrangement or understanding with respect to any Transfer; (iii) grant any
                                         proxy, power-of-attorney or other authorization or consent with respect to any of the
                                         Stockholder Securities with respect to any matter that is in contravention of the obligations
                                         of Stockholder under this Agreement with respect to the Stockholder Securities; or (iv)
                                         deposit any of the Stockholder Securities into a voting trust, or enter into a voting
                                         agreement or arrangement with respect to any of such Stockholder Securities in contravention
                                         of the obligations of Stockholder under this Agreement with respect to the Stockholder
                                         Securities. Any action taken in violation of the foregoing sentence shall be null and
                                         void ab initio. If any involuntary Transfer of any of the Stockholder Securities
                                         shall occur (including, but not limited to, a sale by Stockholder’s trustee in
                                         any bankruptcy, or a sale to a purchaser at any creditor’s or court sale), the
                                         transferee (which term, as used herein, shall include any and all transferees and subsequent
                                         transferees of the initial transferee) shall take and hold such Stockholder Securities
                                         subject to all of the restrictions, liabilities and rights under this Agreement, which
                                         shall continue in full force and effect until the End Date.

 

    -2- 

     

    

  

		(b)	Notwithstanding
                                         the foregoing Section 3(a), any Stockholder may Transfer Stockholder Securities,
                                         (i) if such Stockholder is an individual, (A) to any trust for the benefit of such Stockholder
                                         or any spouse or descendant of such Stockholder for estate planning purposes and (B)
                                         upon the death of such Stockholder, to such Stockholder’s estate, (ii) if such
                                         stockholder is an entity, to any affiliate of such Stockholder and (iii) as Parent may
                                         otherwise agree in writing in its sole discretion, so long as, in the case of each of
                                         the foregoing clauses (i), (ii) and (iii), any such transferee shall agree in writing
                                         to be bound by this Agreement as though such transferee were an original party hereto
                                         in the capacity as a Stockholder prior to the consummation of any such Transfer.

 

		(c)	Stockholder
                                         agrees that it will not exercise any appraisal rights available to Stockholder with respect
                                         to the Merger in accordance with Section 262 of the DGCL.

 

SECTION
4.      Voting of Shares.

 

		(a)	Without
                                         in any way limiting Stockholder’s right to vote the Stockholder Securities in its
                                         sole discretion on any other matters not set forth in Section 4(a)(ii) that may
                                         be submitted to a Stockholder vote, consent or other approval, at any annual, special
                                         or other meeting of the Company’s stockholders called or any action by written
                                         consent in lieu of a meeting of stockholders of the Company with respect to any of the
                                         following, and at any adjournment or postponement thereof, Stockholder (solely in Stockholder’s
                                         capacity as a holder of the Stockholder Securities and not in any other capacity) shall,
                                         or shall cause the holder of record on any applicable record date to, (i) appear at each
                                         such meeting or otherwise cause all of Stockholder’s Stockholder Securities entitled
                                         to vote to be counted as present thereat for purposes of calculating a quorum and (ii)
                                         vote (or cause to be voted), in person or by proxy, all Stockholder Securities beneficially
                                         owned by Stockholder and entitled to vote (A) in favor of (1) the approval of the Merger
                                         Agreement and the approval of the Merger and the other transactions contemplated by the
                                         Merger Agreement and (2) any other matter reasonably necessary to consummate the transactions
                                         contemplated thereby (including the Merger), and (B) against (x) any action or agreement
                                         which could reasonably be expected to impede, interfere with, prevent, delay or adversely
                                         affect the Merger Agreement, the Merger or this Agreement, (y) any Competing Proposal
                                         and (z) any action, proposal, transaction or agreement that could reasonably be expected
                                         to result in a breach of any covenant, representation or warranty or any other obligation
                                         or agreement of Stockholder under this Agreement.

 

		(b)	Notwithstanding
                                         the foregoing, Stockholder shall retain at all times the right to vote the Stockholder
                                         Securities held by it in its sole discretion and without any other limitation on those
                                         matters other than those set forth in Section 4(a)(ii) that are at any time or
                                         from time to time presented for consideration to the Company’s stockholders at
                                         any annual, special or other meeting of the Company’s stockholders or any action
                                         by written consent in lieu of a meeting of the Company’s stockholders.

 

    -3- 

     

    

  

		(c)	The
                                         obligations set forth in this Section 4 shall apply to Stockholder during the
                                         period beginning on the date of this Agreement and ending on the End Date.

 

SECTION
5.      No Solicitation. Subject to Section 6, Stockholder
covenants and agrees that, beginning on the date of this Agreement and ending on the End Date, Stockholder shall not and shall
cause its Representative not to directly or indirectly take any action that the Company is prohibited from taking under Section 5.03
of the Merger Agreement.

 

SECTION
6.      Directors and Officers. Notwithstanding any provision
of this Agreement to the contrary, this Agreement shall apply to Stockholder solely in Stockholder’s capacity as a holder
of the Stockholder Securities and/or other Shares or Company Options and not in Stockholder’s or any partner, officer, employee
or affiliate of Stockholder’s capacity as a director, officer or employee of the Company or any of its Subsidiaries. Notwithstanding
any provision of this Agreement to the contrary, nothing in this Agreement shall limit or restrict any actions or omissions of
any such person in his or her capacity as a director and/or officer of the Company or any of its Subsidiaries or from fulfilling
the duties and obligations of such office, including in the exercise of his or her fiduciary duties as a director and/or officer
of the Company or any of its Subsidiaries.

 

SECTION
7.      Further Assurances. Each party shall execute and
deliver any additional documents and take such further actions that are reasonably necessary to carry out all of its obligations
under the provisions hereof.

 

SECTION
8.      Termination.

 

		(a)	This
                                         Agreement, and all rights and obligations of the parties hereunder, shall terminate immediately
                                         and automatically, and be of no further force and effect, without any notice or other
                                         action by any person, upon the earliest to occur of the following (the date of such termination,
                                         the “End Date”):

 

		(i)	valid
                                         termination of the Merger Agreement in accordance with its terms;

 

		(ii)	the
                                         Effective Time;

 

		(iii)	the
                                         mutual written consent of Parent and Stockholder; or

 

		(iv)	any
                                         change to the terms of the Merger Agreement without the prior written consent of Stockholder
                                         that (A) reduces the Merger Consideration or any other consideration otherwise payable
                                         with respect to the Company Options beneficially owned by Stockholder (subject to adjustments
                                         in compliance with Section 2.01(b) of the Merger Agreement) or (B) changes the form of
                                         consideration payable in the Merger or any consideration otherwise payable with respect
                                         to the Shares or Company Options beneficially owned by Stockholder;

 

    -4- 

     

    

  

		(b)	Upon
                                         termination of this Agreement, all obligations of the parties hereto under this Agreement
                                         will terminate, without any liability or other obligation on the part of any party hereto
                                         to any person in respect hereof or the transactions contemplated hereby, and no party
                                         hereto shall have any claim against another (and no person shall have any rights against
                                         such party), whether under contract, tort or otherwise, with respect to the subject matter
                                         hereof, provided however, that the termination of this Agreement shall not relieve
                                         any party hereto from liability for any willful misrepresentation or willful and material
                                         breach of this Agreement, in each case prior to such termination.

 

		(c)	Sections
                                         8(b), 9 and 12 hereof shall survive the termination of this Agreement.

 

SECTION
9.      Expenses. All fees and expenses incurred in connection
with the negotiation and execution of this Agreement and the transactions contemplated hereby shall be paid by the party incurring
such fees and expenses, whether or not the Merger is consummated.

 

SECTION
10.  Public Announcements. Stockholder shall not make public announcements regarding
this Agreement and the transactions contemplated hereby that are inconsistent with the public statements made by the Company and
Parent in connection with this Agreement, the Merger Agreement and the transactions contemplated thereby, without the prior written
consent of Parent. Stockholder (i) consents to and authorizes (x) the publication and disclosure by the Company, Parent and their
respective affiliates of its identity and beneficial ownership of the Stockholder Securities and the nature of its commitments,
obligations, arrangements and understandings under this Agreement in the Proxy Statement, any current report of the Company on
Form 8-K and any other documents required to be filed with the SEC or other Governmental Entity; provided that, Parent shall provide
Stockholder and its counsel reasonable opportunity to review and comment thereon, and Parent shall give reasonable consideration
to any such comments and (y) the filing by the Company, Parent and their respective affiliates of this Agreement as an exhibit
to the extent required to be filed with the SEC or any Governmental Entity relating to the Merger, and (ii) agrees to promptly
give to the Company and Parent any information they may reasonably require for the preparation of any such disclosure documents.
Parent consents to and authorizes the publication and disclosure by Stockholder of the nature of its commitments and obligations
under this Agreement in connection with the Merger in any Form 4, Schedule 13D, Schedule 13G or other disclosure required by the
SEC or other Governmental Entity to be made by Stockholder in connection with the Merger.

 

SECTION
11.  Adjustments. In the event (a) of reclassification, stock split (including
a reverse stock split), combination, stock dividend or distribution, recapitalization, subdivision, merger, issuer tender or exchange
offer, or other similar transaction or (b) that Stockholder shall become the beneficial owner of any additional Shares or Company
Options, then the terms of this Agreement shall apply to the Shares or Company Options held by Stockholder immediately following
the effectiveness of the events described in clause (a) or Stockholder becoming the beneficial owner thereof as described in clause
(b), as though, in either case, they were Stockholder Securities hereunder. In the event that Stockholder shall become the beneficial
owner of any other securities entitling the holder thereof to vote or give consent with respect to the matters set forth in Section
4(a)(ii) hereof, then the terms of Section 4 hereof shall apply to such other securities as though they were Stockholder
Securities hereunder.

 

    -5- 

     

    

  

SECTION
12.  Miscellaneous.

 

(a)              
Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given
(and shall be deemed to have been duly given upon receipt) by delivery in person, by facsimile or e-mail or by registered or certified
mail (postage prepaid, return receipt requested and providing proof of delivery) to the respective parties hereto at the following
addresses, facsimile numbers or email addresses as follows (or at such other address, facsimile number or email address for a
party as shall be specified by like notice):

 

If
to Stockholder, to:

 

c/o West Marine, Inc.

500 Westridge Drive

Watsonville, California  95076

	 	Attention:	Randolph K. Repass
	 	Email:	As separately provided

 

If to Parent or
Sub, to:

 

c/o
Monomoy Capital Partners III, L.P.

142
West 57th Street, 17th Floor

New
York, NY 10019

	 	Attention:	Daniel Collin
	 	     	Lee Mlotek
	 	E-mail:	dcollin@mcpfunds.com
	 	     	lmlotek@mcpfunds.com

 

with
a copy to (which shall not constitute notice):

 

Kirkland
& Ellis LLP

601 Lexington Avenue

New York, NY 10022

	 	Attention:	Michael Weisser,
    P.C.
	 	 	David Feirstein
	 	Facsimile:	(212) 446-6460
	 	E-mail:	michael.weisser@kirkland.com
	 	 	david.feirstein@kirkland.com

 

 

    -6- 

     

    

 

(b)              
Headings. The descriptive headings contained in this Agreement are included for convenience of reference only and
shall not affect in any way the meaning or interpretation of this Agreement.

 

(c)              
Counterparts. This Agreement may be executed and delivered (including by facsimile transmission, “.pdf,”
or other electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each
of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

(d)              
Entire Agreement, No Third-Party Beneficiaries. This Agreement (i) constitutes the entire agreement among the parties
hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral,
among or between any of the parties hereto, with respect to the subject matter hereof and (ii) is not intended to, nor shall it,
confer upon any other person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement.

 

(e)              
Governing Law, Jurisdiction. This Agreement shall be governed and construed in accordance with the Laws of the State
of Delaware, without regard to any conflicts of laws principles that would result in the application of the Law of any other state
or jurisdiction. Each party agrees that it will bring any action or proceeding in respect of any claim arising out of or related
to this Agreement, the Merger Agreement or the transactions contemplated hereby or thereby exclusively in the Delaware Court of
Chancery (or, if the Delaware Court of Chancery shall be unavailable, any other court of the State of Delaware or any Federal
court sitting in the State of Delaware) and, solely in connection with claims arising under this Agreement, the Merger Agreement
or the transactions contemplated hereby or thereby, (i) irrevocably submits to the exclusive jurisdiction of such court, (ii)
waives any objection to laying venue in any such action or proceeding in such court, (iii) waives any objection that such court
is an inconvenient forum or does not have jurisdiction over any party and (iv) agrees that service of process upon such party
in any such action or proceeding will be effective if notice is given in accordance with Section 12(a).

 

(f)               
Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT
OR THE MERGER AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY
AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY SUIT, ACTION OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF SUIT, ACTION
OR OTHER PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS
WAIVER, (C) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG
OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 12(f).

 

    -7- 

     

    

  

(g)              
Assignment. This Agreement shall not be assigned by operation of law or otherwise without the prior written consent
of each of the other parties hereto, and any assignment without such consent shall be null and void. Subject to the preceding
sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective
successors and permissible assigns.

 

(h)              
Severability of Provisions. If any term or other provision of this Agreement is found by a court of competent jurisdiction
to be invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other conditions and provisions
of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner adverse to any party hereto. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner to the end
that the transactions contemplated hereby are fulfilled to the fullest extent possible.

 

(i)                
Specific Performance. The parties hereto agree that irreparable damage for which monetary damages, even if available,
would not be an adequate remedy would occur in the event that the parties hereto do not perform the provisions of this Agreement
(including any party hereto failing to take such actions as are required of it hereunder in order to consummate the transactions
contemplated by this Agreement) in accordance with its specified terms or otherwise breach such provisions. The parties hereto
acknowledge and agree that, (i) the parties hereto will be entitled, in addition to any other remedy to which they are entitled
at law or in equity, to an injunction, specific performance and other equitable relief to prevent breaches (or threatened breaches)
of this Agreement and to enforce specifically the terms and provisions hereof; and (ii) the right of specific enforcement
is an integral part of the Agreement and without that right, Parent would not have entered into this Agreement. It is accordingly
agreed that each party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled
at law or in equity and any party hereto seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement will not be required to provide any bond or other security in connection
with such injunction or enforcement, and each party hereto irrevocably waives any right that it may have to require the obtaining,
furnishing or posting of any such bond or other security.

 

(j)                
Amendment. No amendment or modification of this Agreement shall be effective unless it shall be in writing and signed
by each of the parties hereto, and no waiver or consent hereunder shall be effective against any party unless it shall be in writing
and signed by such party.

 

(k)              
Binding Nature. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit
of, the parties hereto and their respective successors and permitted assigns.

 

    -8- 

     

    

  

(l)                
No Recourse. Parent and Sub agree that Stockholder will not be liable for claims, losses, damages, expenses and
other liabilities or obligations resulting from or related to the Merger Agreement or the Merger (other than any liability for
claims, losses, damages, expenses and other liabilities or obligations solely to the extent arising under, and in accordance with
the terms of, this Agreement), including the Company’s breach of the Merger Agreement.

 

(m)            
No Presumption. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

 

(n)              
No Agreement Until Executed. This Agreement shall not be effective unless and until (i) the Merger Agreement is
executed by all parties thereto and (ii) this Agreement is executed by all parties hereto.

 

(o)              
No Ownership Interest. Except as otherwise specifically provided herein, nothing contained in this Agreement shall
be deemed to vest in Parent or Sub any direct or indirect ownership or incidence of ownership of or with respect to the Stockholder
Securities. All rights, ownership and economic benefits of and relating to the Stockholder Securities shall remain vested in and
belong to Stockholder, and neither Parent nor Sub shall have any authority to manage, direct, restrict, regulate, govern, or administer
any of the policies or operations of the Company or exercise any power or authority to direct Stockholder in the voting of any
of the Stockholder Securities, except as otherwise specifically provided herein.

 

 

 

[Signature
pages follow]

 

 

 

 

 

 

 

    -9- 

     

    

 

IN
WITNESS WHEREOF, Parent, Sub and Stockholder have caused this Agreement to be duly executed and delivered as of the date first
written above.

 

	 	RISING TIDE
    PARENT INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	 	 
	 	RISING TIDE
    MERGER SUB INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

 

    
[Signature Page—Voting and Support Agreement]

     

    

 

IN
WITNESS WHEREOF, Parent, Sub and Stockholder have caused this Agreement to be duly executed and delivered as of the date first
written above.

 

	 	 	 
	 	By:	 
	 	 	[Stockholder]
	 	 	 

  

    
[Signature Page—Voting and Support Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]